GreeNOR is the easiest adventure to platfrom to go in the future. We provide suppliers access to a platfrom that has locals and turists that love to find and book adventures via GreeNOR. GreeNOR is a startup that has started that journey 1,5 years ago. We have invested in developing a great platfrom and we go already as well Customers in the Balkans and Norway.

Immerse Optics aims to give people sensational experiences using its patented lens technology. We provide experiences for drone pilots (DroneMask series), movie enthusiasts (MovieMask series), and Augmented Reality fans (MagiMask). Our current focus is on the DroneMask, where our lens gives drone pilots the ultimate first-person view camera drone experience. Our high-quality patented lens powers all our products.

We are in indie game developer based out of Oslo, Norway. We have to date launched five games for PC, Switch and mobile platforms. At the moment we develop "Life Below", a creative strategy city-builder where you build and manage ocean ecosystems. So a reef builder! In addition to our own IP, we develop games and gamification projects for society. We call ourselves an impact game developer as many of our projects are focused on positive change to society. Right now we develop a game for all kids going into hospital, a history game to spice up history learning in schools, a city cleaning game using the mascot of Oslo, a climate game and an awareness game tackling difficult issues in relation to sex and identify. Many of our impact projects are successes, and are widely used. Our aim is to make society better, one game at the time.

Our mission is to help food manufacturers reduce food waste and cost through our digital platform. To date, we've successfully transacted over 4.000 tons of food, and we're continuing to scale our business to have an even greater impact. We have ambitious growth plans and are expanding. We recently carried out a rebranding and are in the process of building our product & technology team to scale further.

Sleepytroll is the world's first rechargeable and sensor-controlled baby rocker. It easily attaches to the stroller or car seat, and with adapters, it can also rock the crib. The sensors detect sound and movement from the baby and automatically begin to rock the stroller/car seat/crib. We offer our patented Sleepytroll Baby Rocker, loved by thousands of babies and their parents, to retailers and distributors across the world. Please contact us at post@sleepytroll.com to take part in the success. We wish you all a wonderful day!

Vi er Nolo Nordic og vi gjør alkoholfritt mer spennende, sofistikert, gøy og smakfullt ved å produsere førsteklasses drikkevarer under merkenavnene ALT. og Ambijus. Akkurat nå brygger vi nye nettsider, men besøk gjerne linkene over for å lære mer om våre prisvinnende og kompromissløse alkoholfrie drikker.

50% of the population will encounter mental illness, but 65% leave treatment without results. We're here to change that. We develop the world's first holistic mental healthcare platform designed to improve the effectiveness of psychological treatment. Our SaaS platform for psychologists combines the basic tools needed to administer a private practice, with novel research-based treatment instruments. We are an ambitious team of psychology specialists, business developers, and an advisory board with industry specialists. You can take a look at our team [here](https://www.konfidens.no/team). Mindcare is backed by Innovation Norway, Aleap, and several private investors. We are now hiring our first team members. We're looking for two talented developers to join our company as co-founders and help build the organization and product. Is this you or someone you know? Get in touch!

Norwegian Block Exchange AS (NBX) was established in 2018 and is working with distributed ledger technologies. NBX’s offices are located at Fornebu in Bærum, Norway. NBX is building the next-generation cryptocurrency exchange to set a new standard for security, transparency, and reliability within cryptocurrency trading. We start from scratch and only use the best-in-class solutions and technology. The company will also work on the adaption of DLT to find better and smarter ways for businesses across industries to operate. NBX has global ambitions and to reach the goals we build the company by working with the best people and partners.

Revolusjonen er i gang! Verden endrer seg i et forrykende tempo. Innovasjon og stadig fornyelse er viktigere enn noen gang for å beholde kundene. Moderne teknologi har raskere enn noensinne gjort at IT flytter seg nærmere forretning. Nå må beslutninger tas raskt og «fail fast» er nøkkelord. Revolusjonen har såvidt begynt og i Aboveit forstår vi effekten, virkemidlene og veien til målet.   Aboveit bygger broen mellom teknologi og forretning  - Ved å ta i bruk skyens kapabiliteter hjelper vi deg med å realisere forretningsverdi og å skape fortrinn i markedet. Vi er sikre på at morgendagens vinnere er de som får mest ut av plattformene og tjenestene i skyen. Vår tilnærming til transformasjon og digitalisering vil endre måten våre kunder tenker på sky. Vi er klare for reisen og til å løfte våre kunder til nye høyder. Velkommen til Aboveit - Vi kan hjelpe deg!

We digitize our customers by supporting more business processes with software. The core drivers are better insight and higher consistency. We make use of or create new software that solve each prospect. We are profitable and are looking to expand our offering with a modern platform. Voit offers IT systems that make less use of data with experience from everyday life, production and startups.

Bile duct cancer is an aggressive form of cancer with an extremely poor overall five-year survival rate of just 2-5 %. Classified as an orphan disease, annual incidence in Europe and the United States of 15-22,000 patients, and a significantly higher incidence in Asia, makes it a major player and the deadliest of the gastrointestinal cancers. Only a small number of patients are eligible for a complete surgical resection by local resection or liver transplantation, and more than 50% of these relapse. The vast majority are treated by gemcitabine-based palliative chemotherapy with a life expectancy of 11 months, and five-year survival rate of zero %. Thus, there is an urgent and unmet medical need to develop new and better treatment strategies for these patients. The innovations developed by Seald are a result of adopting a multidisciplinary approach to the diagnosis and treatment of bile duct cancer, based on extensive drug sensitivity assays on living cancer cells, molecular biomarkers, DNA sequencing, extensive bioinformatics analyses and zebrafish models. Sealds’s holistic approach is unique with possible modes of action that can be used on other solid cancers. Our technology includes drug repurposing and innovation on new medical substances, diagnostics and methodology. The stipulated pharma market globally is USD 2.1-4.2 billion, in addition to the markets for diagnostics and platform technology

RESPINOR is a privately-owned medical device company, founded in Oslo, 2015. We have developed an objective measure of breathing for critically ill patients within intensive care. The technology provides precise, continuous and real-time information of diaphragm function, our main breathing muscle, to increase the quality of care and reducing costs. RESPINOR’s technology is the winner of Horizon 2020 both in phase I and II. We are addressing an unmet medical need because every breath counts.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Excitus is set up to develop, manufacture and sell medical suction products based on its revolutionary, patent-pending mobile suction platform. Products will span from professional hand-held tools for paramedics to consumer devices in a private home and stored together with the defibrillator at supermarkets, stadiums, etc. The platform enables a higher survival rate at cardiac arrests, yet at the same time, it provides a razor/razorblade business model unseen in this area.

Fishency Innovation can give access to the entire salmon industry to affordable equipment to count automatically sea lice in the cage. Monitoring sea lice is the key to controlling them, it is access to good decision support for optimized treatments and to a reliable tool to measure the efficiency of preventive measures and existing treatments. Today, sea lice are counted manually over 20 fish, every week, in each cage. It is labor-demanding, and the collected data are not reliable. Sustainability starts with good data.